KKR closed its $5.89 billion acquisition of Integer Holdings in August, completing a take-private that began in spring and now stands as the largest healthcare PE transaction of the quarter. The medical-device manufacturer, which supplies components for cardiac rhythm management and neuromodulation systems, exited public markets at $108.50 per share, a 34% premium to the 30-day VWAP prior to deal announcement. The timing is notable: August global PE deal volume fell 41% year-over-year, yet healthcare absorbed $14.2 billion in private equity capital, more than consumer and industrials combined.
Integer generates $1.48 billion in trailing revenue with 22% EBITDA margins, anchored by long-term supply contracts with Medtronic, Abbott, and Boston Scientific. KKR's healthcare vertical, led by Gaurav Trehan, has been accumulating exposure to the medical-device supply chain since 2021, and Integer fits a pattern: the firm prefers tier-one component suppliers over direct device manufacturers, betting on regulatory moats and switching costs rather than reimbursement risk. The deal was financed with $3.1 billion in debt, arranged by JPMorgan and BofA, at a blended cost near 7.8% — high by 2021 standards, acceptable given Integer's $320 million in unlevered free cash flow.
The counter-cyclical behavior matters. While tech M&A stalled and consumer deals withered under valuation pressure, healthcare PE volume in August alone exceeded the prior quarter's total. Integer's closure suggests that allocators with locked capital are willing to underwrite device-supply businesses at 18-19x forward EBITDA if the customer concentration is managed and the margin profile is durable. That multiple, six months ago, would have triggered internal return hurdles that killed deals. KKR's willingness to clear at this price signals either a view that rate cuts stabilize exit multiples within 24 months, or confidence in operational levers that compress the hold period. The firm has a history of recapitalizing portfolio companies early — Integer could see a dividend recap or bolt-on roll-up within 18 months if cardiac device volumes recover to pre-COVID run rates.
Allocators should track three follow-on events: whether KKR immediately begins consolidating Integer's manufacturing footprint (likely by Q1 2025), whether additional device-supply assets come to market in the next six months (Stryker and Zimmer have both quietly tested buyer interest in non-core component divisions), and whether Integer's customer base accelerates neuromodulation orders (Boston Scientific's spinal cord stimulator franchise is growing 22% annually). The debt structure also bears watching — if KKR refinances the acquisition term loan within 12 months, it signals early confidence in deleveraging and a faster exit than the model assumes.
Integer's employee base of 5,800 across 12 manufacturing sites now operates under private ownership for the first time since 2010. The debt service coverage ratio at close is 1.9x, which leaves room for margin expansion or a modest M&A program without triggering covenant stress. Healthcare remains the only PE vertical where deal closures are accelerating while announcements decline.